Killing the killer: Natural killer cells to treat Ewing's sarcoma

Clinical Cancer Research

Volumn 16, Issue 15, 2010, Pages 3819-3821

  Ahn, Yong Oon ^a   Weigel, Brenda ^a   Verneris, Michael R ^a  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD94 ANTIGEN; CELL ADHESION MOLECULE; CYTOCHROME P450 2B4; DOXORUBICIN; HLA A ANTIGEN; HLA B ANTIGEN; HLA C ANTIGEN; HLA E ANTIGEN; NATURAL CYTOTOXICITY TRIGGERING RECEPTOR; NATURAL KILLER CELL RECEPTOR NKG2A; NATURAL KILLER CELL RECEPTOR NKG2D; PROTEIN DNAM 1; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG; VINCRISTINE;

CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CANCER RELAPSE; CELL FUNCTION; CELL KILLING; CELL STIMULATION; CELL THERAPY; CYTOTOXICITY; DENDRITIC CELL; EWING SARCOMA; HLA SYSTEM; HUMAN; METASTASIS; MULTIMODALITY CANCER THERAPY; NATURAL KILLER CELL; NONHUMAN; NOTE; PRIORITY JOURNAL; T LYMPHOCYTE;

ANIMALS; BONE NEOPLASMS; HUMANS; IMMUNOTHERAPY; KILLER CELLS, NATURAL; MICE; SARCOMA, EWING'S;

EID: 77955117141     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-10-1368     Document Type: Note

References (7)

1. Cho D, Shook DR, Shimasaki N, Chang Y, Fujisaki H, Campana D. Cytotoxicity of activated natural killer cells against pediatric solid tumors. Clin Cancer Res 2010;16:3901-9.
2. Ljunggren HG, Malmberg KJ. Prospects for the use of NK cells in immunotherapy of human cancer. Nat Rev Immunol 2007;7:329-39.
3. Gasser S, Orsulic S, Brown EJ, Raulet DH. The DNA damage pathway regulates innate immune system ligands of the NKG2D receptor. Nature 2005;436:1186-90. (Pubitemid 41232299)
4. Verhoeven DH, de Hooge AS, Mooiman EC, et al. NK cells recognize and lyse Ewing sarcoma cells through NKG2D and DNAM-1 receptor dependent pathways. Mol Immunol 2008;45:3917-25.
5. Imai C, Iwamoto S, Campana D. Genetic modification of primary natural killer cells overcomes inhibitory signals and induces specific killing of leukemic cells. Blood 2005;106:376-83. (Pubitemid 40967217)
6. Fujisaki H, Kakuda H, Shimasaki N, et al. Expansion of highly cytotoxic human natural killer cells for cancer cell therapy. Cancer Res 2009;69:4010-7.
7. Soriani A, Zingoni A, Cerboni C, et al. ATM-ATR-dependent up-regulation of DNAM-1 and NKG2D ligands on multiple myeloma cells by therapeutic agents results in enhanced NK-cell susceptibility and is associated with a senescent phenotype. Blood 2009;113:3503-11.